PRESS RELEASE published on 04/18/2026 at 12:00, 2 months ago Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study Sanofi's Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in a head-to-head study presented at ESCMID Global Congress. Results indicate lower side effects and improved patient experience COVID-19 Sanofi Vaccine Nuvaxovid Tolerability
BRIEF published on 04/13/2026 at 07:05, 2 months 5 days ago Sanofi and Regeneron’s Dupixent Gains EU Approval for Treating Young Children with CSU Sanofi Dupixent EU Approval Regeneron Chronic Spontaneous Urticaria
BRIEF published on 04/13/2026 at 07:05, 2 months 5 days ago Dupixent from Sanofi and Regeneron approved for young children in the EU Children Dupixent Chronic Urticaria Sanofi Regeneron EU Supply
PRESS RELEASE published on 04/13/2026 at 07:00, 2 months 5 days ago Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Sanofi and Regeneron's Dupixent approved in the EU for young children with chronic spontaneous urticaria, expanding treatment options to address type 2 inflammation EU Sanofi Dupixent Regeneron Chronic Spontaneous Urticaria
BRIEF published on 04/07/2026 at 07:05, 2 months 11 days ago Sanofi's Lunsekimig Shows Promise in Asthma and CRSwNP Studies Sanofi CRSwNP Asthma Lunsekimig Phase 2 Studies
PRESS RELEASE published on 04/07/2026 at 07:00, 2 months 11 days ago Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP Sanofi's lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP, showing promising results for managing respiratory diseases Respiratory Diseases Sanofi Asthma Lunsekimig Phase 2 Studies
BRIEF published on 03/28/2026 at 16:05, 2 months 21 days ago Sanofi's Amlitelimab Shows Promising Results in Phase 3 Atopic Dermatitis Studies Clinical Development Sanofi Atopic Dermatitis Phase 3 Studies Amlitelimab
PRESS RELEASE published on 03/28/2026 at 16:00, 2 months 21 days ago Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Positive results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented at AAD Annual Meeting, showing progressive efficacy with Q12W dosing potential Sanofi Phase 3 Atopic Dermatitis Amlitelimab Q12W
BRIEF published on 03/27/2026 at 13:05, 2 months 22 days ago Sanofi's Sarclisa SC Recommended for EU Approval Sanofi Multiple Myeloma EU Approval Sarclisa SC On-Body Injector
BRIEF published on 03/27/2026 at 13:05, 2 months 22 days ago Sanofi: EU approval recommended for subcutaneous Sarclisa Sanofi Multiple Myeloma Sarclisa CHAMP Portable Injector
Published on 06/18/2026 at 23:00, 7 minutes ago Jaguar Mining Inc. Annual General Meeting of Shareholders Voting Results
Published on 06/18/2026 at 18:00, 5 hours 7 minutes ago BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4
Published on 06/18/2026 at 17:30, 5 hours 37 minutes ago Sekur Private Data Appoints Nathan R. Price as Special Advisor for Diplomacy & Intelligence
Published on 06/18/2026 at 15:50, 7 hours 17 minutes ago Pentagon I Capital Corp. and Prospectiva Resources Ltd. Announce Financing
Published on 06/18/2026 at 15:00, 8 hours 7 minutes ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Published on 06/18/2026 at 22:35, 32 minutes ago Bitmine Immersion Technologies Announces Cash Dividend of $0.1056 per Share of 9.50% Series A Perpetual Preferred Stock
Published on 06/18/2026 at 22:00, 1 hour 7 minutes ago Blue Cap AG: Closing of the Acquisition of Janoschka AG Successfully Completed
Published on 06/18/2026 at 18:30, 4 hours 37 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/18/2026 at 18:00, 5 hours 7 minutes ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 5 hours 22 minutes ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 5 hours 28 minutes ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 09:06, 14 hours 1 minute ago Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany